ArticleAnnals of hematology2025
A novel ubiquitination-based molecular signature predicts prognosis in diffuse large B-cell lymphoma.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ubiquitin E3 ligase KLHL6 brings exhausted T-cells back into action.Immunity & inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse Large B-Cell Lymphoma (DLBCL) exhibits significant biological heterogeneity, leading to diverse clinical outcomes. Ubiquitination, a post-translational modification process, plays a crucial regulatory role in tumor development and progression. The prognostic profile of ubiquitinated genes in DLBCL needs to be explored. We analyzed three datasets (GSE181063, GSE56315, and GSE10846) to identify ubiquitination-related survival-associated differentially expressed genes (DEGs) in DLBCL. We constructed a ubiquitination-based prognostic signature and calculated risk scores. Using R software, we investigated relationships between the identified DEGs, high- and low-risk groups, immune microenvironment, drug sensitivity, and single-cell composition. Three key ubiquitination-related survival-associated DEGs were identified: Cell Division Cycle 34 (CDC34), Fizzy-related protein homolog 1 (FZR1), and OTU Deubiquitinase with Linear Linkage Specificity (OTULIN). Elevated expression of CDC34 and FZR1, coupled with low expression of OTULIN, correlated with poor prognosis in DLBCL. These genes correlation with endocytosis-related mechanisms, T-cell, and drugs sensitive. Significant differences in immune scores and concentration for Boehringer Ingelheim compound 2536 and Osimertinib were observed between high- and low-risk groups. This study establishes a novel ubiquitination-based prognostic signature for DLBCL, offering insights into potential therapeutic targets and strategies for personalized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.